Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany.
about
Economic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South KoreaTrade-off between benefits, harms and economic efficiency of low-dose CT lung cancer screening: a microsimulation analysis of nodule management strategies in a population-based setting.Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature.Comparative Effectiveness of Up To Three Lines of Chemotherapy Treatment Plans for Metastatic Colorectal Cancer
P2860
Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Cost-Effectiveness of an Indiv ...... carcinoma Patients in Germany.
@en
type
label
Cost-Effectiveness of an Indiv ...... carcinoma Patients in Germany.
@en
prefLabel
Cost-Effectiveness of an Indiv ...... carcinoma Patients in Germany.
@en
P2093
P2860
P1433
P1476
Cost-Effectiveness of an Indiv ...... ocarcinoma Patients in Germany
@en
P2093
Amanda L H Tufman
Katharina Schremser
Rudolf M Huber
Sigrid Adler-Reichel
Wolf H Rogowski
P2860
P2888
P304
P356
10.1007/S40273-015-0305-8
P577
2015-11-01T00:00:00Z
P6179
1053545126